The inhibitory effect on the IFN-1 genes was significantly more pronounced than that observed with riociguat, suggesting that modulation of sGC with an sGC activator may lead to deeper inhibition of key SSc-associated pathways (i.e. IFN-1) than with an sGC stimulator. Here, SGCB is linked to systemic sclerosis.